0 24

Cited 0 times in

Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome

Authors
 Shin Hye Kim  ;  Hoon-Chul Kang  ;  Joon Soo Lee  ;  Heung Dong Kim 
Citation
 Brain & Development, Vol.40(10) : 897-903, 2018 
Journal Title
 Brain & Development 
ISSN
 0387-7604 
Issue Date
2018
MeSH
Adjuvants, Pharmaceutic ; Anticonvulsants/administration & dosage ; Anticonvulsants/adverse effects ; Anticonvulsants/pharmacology* ; Child, Preschool ; Female ; Humans ; Infant ; Lennox Gastaut Syndrome/drug therapy* ; Male ; Outcome Assessment (Health Care)* ; Retrospective Studies ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Triazoles/pharmacology*
Keywords
Efficacy ; Lennox–Gastaut syndrome ; Pediatric ; Rufinamide ; Safety
Abstract
PURPOSE: The treatment options for Lennox-Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1-4 years. METHODS: This was a retrospective, observational study in LGS patients aged 1-4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50% reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. RESULTS: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67%) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23% by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. CONCLUSION: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1-4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs.
Full Text
https://www.sciencedirect.com/science/article/pii/S038776041830384X
DOI
10.1016/j.braindev.2018.07.020
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
강훈철(Kang, Hoon Chul) ORCID logo https://orcid.org/0000-0002-3659-8847
김흥동(Kim, Heung Dong) ORCID logo https://orcid.org/0000-0002-8031-7336
이준수(Lee, Joon Soo) ORCID logo https://orcid.org/0000-0001-9036-9343
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167442
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse